Search research articles
Contact Us
Filters
Showing results (171-180 of 397) with videos related to
Page
of 40
Sort By:
BMJ Oncology
|
January 31, 2025
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours
Aung Naing, Kyriakos P Papadopoulos, Michael J Pishvaian, et al.
The Oncologist
|
March 17, 2021
Overview of Ocular Side Effects of Selinexor
Nagham Al-Zubidi, Dan S Gombos, David S Hong, et al.
The Oncologist
|
October 25, 2013
Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit
Siqing Fu, Lacey McQuinn, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2014
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses
Apostolia-Maria Tsimberidou, Sijin Wen, David S Hong, et al.
Cancer Medicine
|
February 24, 2024
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors
Niamh Coleman, Bettzy Stephen, Siqing Fu, et al.
Oncoscience
|
January 17, 2015
Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
Gerald S Falchook, Aung Naing, Jennifer J Wheler, et al.
Oncotarget
|
July 9, 2014
Characteristics and survival of patients with advanced cancer and p53 mutations
Rabih Said, Yang Ye, David S Hong, et al.
Investigational New Drugs
|
February 13, 2021
Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial
Anas Alshawa, Alexandra Perez Cadena, Bettzy Stephen, et al.
Oncotarget
|
May 15, 2013
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy
Rabin Said, David S Hong, Carla L Warneke, et al.
Critical Reviews in Oncology/Hematology
|
April 22, 2017
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta, Roberto Borea, Andreia Coelho, et al.
Page
of 40
Search research articles
Search
Showing results (171-180 of 397) with videos related to
Sort By:
Page
of 40
BMJ Oncology
|
January 31, 2025
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours
Aung Naing, Kyriakos P Papadopoulos, Michael J Pishvaian, et al.
The Oncologist
|
March 17, 2021
Overview of Ocular Side Effects of Selinexor
Nagham Al-Zubidi, Dan S Gombos, David S Hong, et al.
The Oncologist
|
October 25, 2013
Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit
Siqing Fu, Lacey McQuinn, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2014
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses
Apostolia-Maria Tsimberidou, Sijin Wen, David S Hong, et al.
Cancer Medicine
|
February 24, 2024
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors
Niamh Coleman, Bettzy Stephen, Siqing Fu, et al.
Oncoscience
|
January 17, 2015
Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
Gerald S Falchook, Aung Naing, Jennifer J Wheler, et al.
Oncotarget
|
July 9, 2014
Characteristics and survival of patients with advanced cancer and p53 mutations
Rabih Said, Yang Ye, David S Hong, et al.
Investigational New Drugs
|
February 13, 2021
Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial
Anas Alshawa, Alexandra Perez Cadena, Bettzy Stephen, et al.
Oncotarget
|
May 15, 2013
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy
Rabin Said, David S Hong, Carla L Warneke, et al.
Critical Reviews in Oncology/Hematology
|
April 22, 2017
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta, Roberto Borea, Andreia Coelho, et al.
Page
of 40